Show results for
Refine by
Cancer Nsclc Equipment & Supplies
64 equipment items found
Manufactured by:Lineage Cell Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from our pluripotent cell technology using a directed differentiation method, is comprised of a population of mature dendritic cells. As the most potent type ...
Manufactured by:GeneCentric Therapeutics, Inc. based inDurham, NORTH CAROLINA (USA)
GeneCentric has developed two gene expression profilers (LSP 210 and LSP 220) that define molecular subtypes of the two most common forms of non-small cell lung cancer (NSCLC), squamous cell carcinoma, and ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our product is a new-generation CAP6 that shows great promise as a highly effective treatment for lung cancer (NSCLC). Lung cancer is one of the most widely prevalent cancers, and one of the most difficult to treat. Eighty-one percent of patients treated for lung cancer die within five ...
Manufactured by:Eagle Pharmaceuticals, Inc. based inWoodcliff Lake, NEW JERSEY (USA)
Indication: PEMFEXY is indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). PEMFEXY is indicated as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer ...
by:F. Hoffmann-La Roche Ltd. based inBasel, SWITZERLAND
Alecensa is a highly selective, central nervous system-active, oral medicine used for the treatment of people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK)-positive. Alecensa is a tyrosine kinase inhibitor that targets ALK fusion proteins, preventing signalling within cancer cells to ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HANBEITAI (bevacizumab injection) was approved by the NMPA in November 2021. It is indicated for metastatic colorectal cancer (mCRC), advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent glioblastoma, cervical cancer, epithelial ovarian cancer, fallopian tube cancer or ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled cell division during tumor growth.4 Mutations in the p53 protein lead to uncontrolled tumor progression and growth.4 Similar to Kristen rat sarcoma (KRAS), p53 mutations ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. UpRi is being studied in UPLIFT, a single-arm ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers ...
Manufactured by:Amoy Diagnostics Co., Ltd. based inXiamen, CHINA
Lung cancer is one of the most common malignant tumor, and 80~85% of lung cancers are non-small cell lung cancer (NSCLC). There are many driver mutations in NSCLC. The frequency of mutations in patients with NSCLC for the EGFR gene is 10~35%, for KRAS 15?25%, for BRAF1-4%, for NRAS is 1%, for ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
The Kita-Kyushu Lung Cancer antigen-1 (KK-LC-1) is a cancer/testis antigen (CTA) that is expressed in multiple solid tumors while restricted to germ line cells in normal tissues. T-Cure estimates that KK-LC-1 is expressed in 80% gastric cancer, 75% triple negative breast cancer (TNBC), 45% non-small cell lung ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Apratastat (TMI-005) is an orally active, non-selective and reversible TACE/MMPs inhibitor, can inhibit inhibit the release of TNF-α. Apratastat has the potential to overcome radiotherapy-resistance in non-small cell lung cancer (NSCLC)[1][2]. Apratastat is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo ...